[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][.
For the development of a clinical vaccine against P. aeruginosa infections we cloned the genes for the main outer membrane proteins F and I of P. aeruginosa and characterized protective epitopes by monoclonal antibodies. A recombinant hybrid protein (OprFaa190-342-OprIaa21-83) was expressed in E. coli which represents the protective epitopes. The vaccine showed to be highly protective in mice against experimental P. aeruginosa infections. A phase I trial in human volunteers showed that the vaccine is well tolerated and that high antibody titers against P. aeruginosa were induced.
von Specht
B U
BU
Abteilung Allgemeine Chirurgie mit Poliklinik, Chirurgische Universitätsklinik Freiburg.
D000942:Antigens, Bacterial / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology*; D003001:Cloning, Molecular; D006801:Humans; D011550:Pseudomonas aeruginosa / Q000276:immunology*
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines